2023年

1. Ohara M, Suda G, Kohya R, Sasaki T, Yoda T, Yoshida S, Fu Q, Yang Z, Hosoda S, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N.(2023) Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma. Front Nutr.10:1272728.
2. Nishimura Y, Ono M, Okubo N, Sone T, Higashino M, Matsumoto S, Kubo M, Yamamoto K, Ono S, Ohnishi S, Sakamoto N. (2023) Application of polyglycolic acid sheets and basic fibroblast growth factor to prevent esophageal stricture after endoscopic submucosal dissection in pigs. J Gastroenterol.58(11):1094-1104.
3. Kohya R, Suda G, Ohara M, Sasaki T, Yoda T, Sakurai N, Yoshida S, Fu Q, Yang Z, Hosoda S, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N. (2023) Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel).15(12):3257.
4. Sasaki T, Suda G, Ohara M, Hosoda S, Kawagishi N, Kohya R, Yoda T, Maehara O, Ohnishi S, Yoshida S, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Komukai S, Ogawa K, Sakamoto N. (2023) Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan. Hepatol Res.53(10):960-967.
5. Tokuchi Y, Suda G, Kawagishi N, Ohara M, Kohya R, Sasaki T, Yoda T, Maehara O, Ohnishi S, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N. (2023) Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper-LDL cholesterolemia without an increase in body weight. Hepatol Res. 53(7):595-606.
6. Murata M, Nezu T, Takebe H, Hirose Y, Okubo N, Saito T, Akazawa T. (2023) Human dentin materials for minimally invasive bone regeneration: Animal studies and clinical cases. J Oral Biosci. 65(1):13-18.
7. Yang Z, Suda G, Maehara O, Ohara M, Yoda T, Sasaki T, Kohya R, Yoshida S, Hosoda S, Tokuchi Y, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Sakamoto N. (2023) Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel).15(3):593.
8. Kawagishi N, Suda G, Yamamoto Y, Baba M, Furuya K,Maehara O, Ohnishi S, Yoshida S, Fu Q, Yang Z, Hosoda S, Tokuchi Y, Kitagataya T, Ohara M, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N. (2023) Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C. Viruses.15(1):181.
9. Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, Hosoda S, Yoshida S, Kubo A, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Kobayashi T, Tsunematsu I, Sakamoto N. (2023) Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis. J Med Virol. 95(2):e28452.

2022年

1. Hosoda S, Suda G, Sho T, Ogawa K, Kimura M, Yang Z, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N.(2022) Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment. Liver Cancer. 12(2):156-170.
2. Kawagishi N, Suda G, Sakamori R, Matsui T, Onozawa M, Yang Z, Yoshida S, Ohara M, Kimura M, Kubo A, Maehara O, Fu Q, Hosoda S, Tokuchi Y, Suzuki K, Nakai M, Sho T, Morikawa K, Natsuizaka M, Ogawa K, Sakai H, Ohnishi S, Takehara T, Sakamoto N. (2022) Serum IL-1β predicts de-novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy. Sci Rep. 12(1):16800.
3. Matsuzawa Y, Okubo N, Tanaka S, Kashiwazaki H, Kitagawa Y, Ohiro Y, Mikoya T, Akazawa T, Murata M. (2022) Primary Teeth-Derived Demineralized Dentin Matrix Autograft for Unilateral Maxillary Alveolar Cleft during Mixed Dentition. J Funct Biomater.13(3):153.
4. Miyazawa M, Aikawa M, Takashima J, KobayashiH, Ohnishi S, Ikada Y.(2022) Pitfalls and promises of bile duct alternatives: A narrative review. World J Gastroenterol. in press.
5. Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, Fu Q, Yang Z, Kimura M, Kitagataya T, Maehara O,Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Suzuki K, Izumi T, Meguro T, Terashita K, Takagi T, Ito J, Kobayashi T, Miyagishima T, Sakamoto N. (2022) Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. Cancers (Basel). 14(16):3938.
6. Takamiya S, Kawabori M, Yamazaki K, Yamaguchi S, Tanimori A, Yamamoto K, Ohnishi S, Seki T, Konno K, Tha KK, Hashimoto D, Watanabe M, Houkin K, Fujimura M. (2022) Intravenous transplantation of amnion-derived mesenchymal stem cells promotes functional recovery and alleviates intestinal dysfunction after spinal cord injury. PLoS One. 17(7):e0270606.
7. Fu Q, Ohnishi S, Goki Suda, Naoya Sakamoto. (2022) Small-molecule inhibitor cocktail promotes the proliferation of pre-existing liver progenitor cells. Stem Cell Reports. in press
8. Murata M, Kabir MA, Hirose Y, Ochi M, Okubo N, Akazawa T, Kashiwazaki H. (2022) Histological Evidences of Autograft of Dentin/Cementum Granules into Unhealed Socket at 5 Months after Tooth Extraction for Implant Placement. J Funct Biomater.13(2):66.
9. Yoshida S, Suda G, Ohara M, Kimura M, Yang Z, Maehara O, Fu Q, Hosoda S, Akinori K, Tokuchi Y, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. (2022) Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis. Hepatol Res. Epub ahead of print.
10. Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, Sugiura R, Kimura M, Maehara O, Yamada R, Kitagataya T, Shigesawa T, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. (2022) Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS One. 17(1):e0261760.
11. Nahata M, Fujitsuka N, Sekine H, Shimobori C, Ohbuchi K, Iizuka S, Mogami S, Ohnishi S, Takeda H. (2022) Decline in Liver Mitochondria Metabolic Function Is Restored by Hochuekkito Through Sirtuin 1 in Aged Mice With Malnutrition. Front Physiol.13:848960.
12. Nakamura A, Yamamoto K, Takeda R, Yamada R, Kubo A, Morikawa K, Ando S, Shimazaki T, Izumi T, Umemura M, Kitagataya T, Shigesawa T, Suzuki K, Kimura M, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Ohnishi S, Sugiyama T, Takeda H, Sakamoto N. (2022) The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. Hepatol Res.
13. Yang Z*, Suda G*, Maehara O*(* contributed equally), Ohara M, Yoshida S, Hosoda S, Kimura M, Kubo A, Tokuchi Y, Fu Q, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. (2022) Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers. 14(1):232.

2021年

1. Yamada C, Hattori T, Ohnishi S, Takeda H. (2021) Ghrelin Enhancer, the Latest Evidence of Rikkunshito. Front Nutr. 8:761631.
2. Yamamoto K, Kondo Y, Ohnishi S, Yoshida M, Sugiyama T, Sakamoto N. (2021) The TLR4-TRIF-type 1 IFN-IFN-γ pathway is crucial for gastric MALT lymphoma formation after Helicobacter suis infection. iScience. 24(9):103064.
3. Nahata M, Mogami S, Sekine H, Iizuka S, Okubo N, Fujitsuka N, Takeda H. (2021) Bcl-2-dependent autophagy disruption during aging impairs amino acid utilization that is restored by hochuekkito. NPJ Aging Mech Dis. 7(1):13.
4. Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Ohara M, Yamada R, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. (2021) Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. Sci Rep. 11(1):16616.
5. Yoshida S, Suda G, Ohara M, Fu Q, Yang Z, Hosoda S, Kimura M, Akinori K, Tokuchi Y, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Maehara O, Ohnishi S, Sakamoto N. (2021) Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. Nutrients. 13(7):2415.
6. Kubo A, Suda G, Kimura M, Maehara O, Tokuchi Y, Kitagataya T, Ohara M, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. (2021) Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. Cancers (Basel). 13(14):3633.
7. Maehara O, Suda G, Natsuizaka M, Shigesawa T, Kanbe G, Kimura M, Sugiyama　M, Mizokami M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohashi S, Kagawa S, Kinugasa H, Naganuma S, Okubo N, Ohnishi S, Takeda H, and Sakamoto N. (2021) FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma. Cancer Biol Ther. 22(5-6):372-380.
8. Kawagishi N, Suda G, Kimura M, Maehara O, Yamada R, Tokuchi Y, Kubo A, Kitagataya T, Shigesawa T, Suzuki K, Ohara M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N. (2021) Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. Sci Rep. 11(1):9207.
9. Shigesawa T, Suda G, Kimura M, Maehara O, Tokuchi Y, Kubo A, Yamada R, Furuya K, Baba M, Kitagataya T, Suzuki K, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. (2021) Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. PLoS One. 16(3): e0247728.
10. Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Ohara M, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. (2021) Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass. J Viral Hepat. 28(5):755-763.
11. Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Shigesawa T, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N. (2021) Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatol Res. 51(9):979-989.
12. Ohnishi S, Ariyoshi K, Oyamada S, Kihara K, Konno Y, Watari H.(2021) Efficacy of rikkunshito on chemotherapy-induced nausea and vomiting in patients with uterine corpus or cervical cancer treated with cisplatin-based regimen -placebo-controlled, double-blind, randomized confirmatory study (Efficacy of rikkunshito on chemotherapy-induced nausea and vomiting). Medicine Case Reports and Study Protocols. 2(6); e0109.
13. Kinowaki S, Shimizu Y, Ono M, ZiJian Y, Tanaka I, Shimoda Y, Inoue M, Ishikawa M, Yamamoto K, Ono S, Ohnishi S, Sakamoto N.(2021) Experiment on endoscopic balloon dilation for esophageal stenosis after endoscopic submucosal dissection in pigs. J Gastroenterol. 56(6):527-536.
14. Furukawa JI, Hanamatsu H, Yokota I, Hirayama M, Ando T, Kobayashi H, Ohnishi S, Miura N, Okada K, Sakai S, Yuyama K, Igarashi Y, Ito M, Shinohara Y, Sakamoto N. (2021) A comprehensive glycomic approach reveals novel low-molecular weight blood group-specific glycans in serum and cerebrospinal fluid. Journal of Proteome Research. 7;20(5):2812-2822
15. Takahashi H, Ohnishi S, Yamamoto Y, Hayashi T, Murao N, Osawa M, Maeda T, Ishikawa K, Sakamoto N, Funayama E.(2021) Topical application of conditioned medium from hypoxically cultured amnion-derived mesenchymal stem cells promotes wound healing in diabetic mice.Plastic and Reconstructive Surgery. 147(6):1342-1352.
16. Ohkawara T., Okubo N., Maehara O., Nishihira J., Takeda H. (2021) Protective effect of ISO-1 with inhibition of RIPK3 up-regulation and neutrophilic accumulation on acetaminophen-induced liver injury in mice. Toxicol Lett. 339 51-59.
17. Suzuki K., Suda G., Yamamoto Y., Furuya K., Baba M., Nakamura A., Miyoshi H., Kimura M., Maehara O., Yamada R., Kitagataya T., Yamamoto K., Shigesawa T., Nakamura A., Ohara M., Kawagishi N., Nakai M., Sho T., Natsuizaka M., Morikawa K., Ogawa K., Ohnishi S., Sakamoto N. (2021) Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 56(2) 168-180.
18. Shigesawa T*, Maehara O*, Suda G* (* contributed equally), Natsuizaka M, Kimura M, Shimazaki T, Yamamoto K, Yamada R, Kitagataya T, Nakamura A, Suzuki K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohnishi S, Sugiyama M, Mizokami M, Takeda H, Sakamoto N. (2021) Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. Carcinogenesis.42: 58-69.
19. Yamasaki K, Zhao S, Nishimura M, Shimizu Y, Tamaki N, Takeda H, Kuge Y. (2021) Effects of feeding condition on the myocardial and hepatic accumulation of radioiodine-labeled BMIPP in mice. Ann Nucl Med. 35: 59

2020年

1. Suda G., Ogawa K., Kimura M., Maehara O., Kitagataya T., Ohara M., Tokuchi Y., Kubo A., Yamada R., Shigesawa T. , Suzuki K., Kawagishi N., Nakai M., Sho T., Natsuizaka M., Morikawa K., Sakamoto N. (2020) Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19. Hepatol Res. 50(10) 1196-1200.
2. Kawagishi N., Suda G., Kimura M., Maehara O., Shimazaki T., Yamada R., Kitagataya T., Shigesawa T., Suzuki K., Nakamura A., Ohara M., Umemura M., Nakai M., Sho T., Natsuizaka M., Morikawa K., Ogawa K., Kudo Y., Nishida M., Sakamoto N. (2020) High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. Hepatol Res. 50(6) 671-681.
3. Ohara M., Suda G., Kimura M., Maehara O., Shimazaki T., Shigesawa T., Suzuki K., Nakamura A., Kawagishi N., Nakai M., Sho T., Natsuizaka M., Morikawa K., Ogawa K., Kobayashi T., Uebayashi M., Takagi R., Yokota I., Shimamura T., Sakamoto N. (2020) Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Hepatol Res. 50(6) 715-725.
4. Shigesawa T., Suda G., Kimura M., Shimazaki T., Maehara O., Yamada R., Kitagataya T., Suzuki K., Nakamura A., Ohara M., Umemura M., Kawagishi N., Nakai M., Sho T., Natsuizaka M., Morikawa K., Ogawa K., Sakamoto N. (2020) Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. JGH OPEN. 4(5) 880-888.
5. Kitagataya T., Suda G., Nagashima K., Katsurada T., Yamamoto K., Kimura M., Maehara O., Yamada R., Shigesawa T., Suzuki K., Nakamura A., Ohara M., Umemura M., Kawagishi N., Nakai M., Sho T., Natsuizaka M., Morikawa K., Ogawa K., Ohnishi S., Komatsu Y., Hata H., Takeuchi S., Abe T., Sakakibara-Konishi J., Teshima T., Homma A., Sakamoto N. (2020) Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. J Gastroenterol Hepatol. 35(10) 1782-1788.
6. Sho T., Suda G., Ogawa K., Kimura M., Shimazaki T., Maehara O., Shigesawa T., Suzuki K., Nakamura A., Ohara M., Umemura M., Kawagishi N., Natsuizaka　M., Nakai M., Morikawa K., Furuya K., Baba M., Yamamoto Y., Kobayashi T., Meguro T., Saga A., Miyagishima T., Yokoo H., Kamiyama T., Taketomi A., Sakamoto N. (2020) Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting JGH OPEN. 4(1) 54-60.
7. Higashikawa K, Horiguchi S, Tarisawa M, Shibata Y, Ohkura K, Yasui H, Takeda H, Kuge Y. (2020) Preclinical investigation of potential use of thymidine phosphorylase-targeting tracer for diagnosis of nonalcoholic steatohepatitis. Nucl Med Biol. 83: 25-32.
8. Yamada C, Iizuka S, Nahata M, Hattori T, Takeda H. (2020) Vulnerability to psychological stress-induced anorexia in female mice depends on blockade of ghrelin signal in nucleus tractus solitarius. Br J Pharmacol. 177: 4666-4682.

2019年

1. Suzuki K., Suda G., Yamamoto Y., Furuya K., Baba M., Kimura M., Maehara O., Shimazaki T., Yamamoto K., Shigesawa T., Nakamura A., Ohara M., Kawagishi N., Nakai M., Sho T., Natsuizaka M, Morikawa K., Ogawa K., Sakamoto N. (2019) Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. Hepatol Res. 49(11) 1294-1304.
2. Suda G., Kimura M., Shigesawa T., Suzuki K., Nakamura A., Ohara M., Kawagishi N., Nakai M., Sho T., Maehara O., Shimazaki T., Morikawa K., Natsuizaka M., Ogawa K., Sakamoto N. (2019) Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs. Hepatol Res. 49(11) 1275-1285.
3. Suda G., Nakai M., Sho T., Kimura M., Shimazaki T., Maehara O., Shigesawa T., Suzuki K., Nakamura A., Ohara M., UmemuraM., Kawagishi N., Baba M., Natsuizaka M., Morikawa K., Ogawa K., Sakamoto N. (2019) The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. Intern Med. 58(7) 943-947.
4. Maehara O., Ohnishi S., Asano A., Suda G., Natsuizaka M., Nakagawa K., Kobayashi M., Sakamoto N., Takeda H. (2019) Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines. Neoplasia. 21(6) 545-556.
5. Sho T., Suda G., Kimura M., Shimazaki T., Maehara O., Shigesawa T., Suzuki K., Nakamura A., Ohara M., Umemura M., Izumi T., Kawagishi N., Baba M., Nakai M., Natsuizaka M., Morikawa K., Ogawa K., Sakamoto N. (2019) Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. Intern Med. 58(6) 797-802.

2018年

1. Miyashita T., Kono T., Matsui D., Yamazaki Y., Sadatomi D., Fujitsuka N., Nakamura S., Okamoto K., Makino I., Kinoshita J., Nakamura K., Hayashi H., Oyama K., Tajima H., Takamura H., Ninomiya I., Fushida S., Mukaisho K., Harmon JW., Ohta T. (2018) Preventive effect of oral hangeshasinto (TJ-14) on the development of reflux-induced esophageal cancer in a surgical rat model. Surgery (in press).
2. Ohara M., Ogawa K., Suda G., Kimura M., Maehara O., Shimazaki T., Suzuki K., Nakamura A., Umemura M., Izumi T., Kawagishi N., Nakai M., Sho T., Natsuizaka M., Morikawa K., Ohnishi S., Sakamoto N. (2018) L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. Hepatol Commun. 2(8) 906-918.
3. Ohara M., Ohnishi S., Hosono H., Yamamoto K., Fu Q., Maehara O., Suda G., Sakamoto N. (2018) Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats. Fron Pharmacol. 9: 709.
4. Kawagishi N., Suda G., Nakamura A., Kimura M., Maehara O., Suzuki K., Nakamura A., Ohara M., Izumi T., Umemura M., Nakai M., Sho T., Natsuizaka M., Morikawa K., Ogawa K., Kudo Y., Nishida M., Miyoshi H., Sakamoto N. (2018) Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS One. 13(12) e0209615.
5. Ohara M., Ohnishi S., Hosono H., Yamamoto K., Yuyama K., Nakamura H., Fu Q., Maehara O., Suda G., Sakamoto N. (2018) Extracellular Vesicles from Amnion-Derived Mesenchymal Stem Cells Ameliorate Hepatic Inflammation and Fibrosis in Rats. Stem Cells Int. 3212643.
6. Tanaka H, Watanabe A, Konishi M, Nakai Y, Yoshioka H, Ohkawara T, Takeda H, Harashima H, Akita H. (2018) The delivery of mRNA to colon inflammatory lesions by lipid-nano-particles containing environmentally-sensitive lipid-like materials with oleic acid scaffolds. Heliyon. 4: e00959.
7. Ide S, Yamamoto R, Takeda H, Minami M. (2018) Bidirectional brain-gut interactions: Involvement of noradrenergic transmission within the ventral part of the bed nucleus of the stria terminalis. Neuropsychopharmacol Rep. 38: 37-43.
8. Ide S, Yamamoto R, Suzuki H, Takeda H, Minami M. (2018) Roles of noradrenergic transmission within the ventral part of the bed nucleus of the stria terminalis in bidirectional brain-intestine interactions. Neuropsychopharmacol Rep. 38:182-188.
9. Onuma T, Kamishima T, Shimamura T, Kawamura N, Yamashita K, Sutherland K, Takeda H. (2018) Longitudinal CT study of sarcopenia due to hepatic failure after living donor liver transplantation. Quant Imaging Med Surg. 8: 25-31.
10. M Ohta, N Chosa, S Kyakumoto, S Yokota, N Okubo, A Nemoto, M Kamo, S Joh, K Satoh, A Ishisaki, IL 1β and TNF α suppress TGF β promoted NGF expression in periodontal ligament derived fibroblasts through inactivation of TGF β induced Smad2/3 and p38 MAPK mediated signals., Int J Mol Med.2018,42,1484-1494.
11. 1. Takeda H. Environmental Factors. In: Functional Dyspepsia: Evidences in Pathophysiology and Treatment 1st ed. Tominaga K and Kusunoki H, editors. Springer Nature Singapore (Singapore). 2018, pp25-38. doi: 10.1007/978-981-13-1074-4

2017年

1. Ibata M., Iwasaki J., Fujioka Y., Nakagawa K., Darmanin S., Onozawa M., Hashimoto D., Ohba Y., Hatakeyama S., Teshima T., Kondo T. (2017). Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities. Cancer Sci. 108:200-207.
2. Wada Y, Kamishima T, Shimamura T, Kawamura N, Yamashita K, Sutherland K, Takeda H. (2017). Pre-operative volume rather than area of skeletal muscle is a better predictor for post-operative risks for respiratory complications in living-donor liver transplantation. Br J Radiol. 90: 20160938.
3. Miyamoto S, Ohnishi S, Onishi R, Tsuchiya I, Hosono H, Katsurada T, Yamahara K, Takeda H, Sakamoto N. (2017). Therapeutic effects of human amnion-derived mesenchymal stem cell transplantation and conditioned medium enema in rats with trinitrobenzene sulfonic acid-induced colitis. Am J Transl Res. 9: 940-952.
4. Maehara O, Suda G, Natsuizaka M, Ohnishi S, Komatsu Y, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Shimazaki T, Kimura M, Asano A, Fujimoto Y, Ohashi S, Kagawa S, Kinugasa H, Naganuma S, Whelan KA, Nakagawa H, Nakagawa K, Takeda H, Sakamoto N. (2017) Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis. 38:1073-1083.
5. Ohkawara T, Takeda H, Nishihira J. (2017). Protective effect of chlorogenic acid on the inflammatory damage of pancreas and lung in mice with l-arginine-induced pancreatitis. Life Sci. 190: 91-96.
6. Matsumoto C, Yamada C, Sadakane C, Nahata M, Hattori T, Takeda H. (2017). Psychological stress in aged female mice causes acute hypophagia independent of central serotonin 2C receptor activation. PLoS One. 12: e0187937.
7. Kono T, Shimada M, Nshi M, Morine Y, Yoshikawa K, Katsuno H, Maeda K, Koeda K, Morita S, Watanabe M, Kusano M, Sakamoto J, Saji S, Sokuoka H, Ohtake Y, Sato Y, Kenematsu T, Kitajima M. (2017) Daikenchuto administration for intestinal hypomotility after open abdominal surgery: a pooled analysis of three randomized controlled trials. Ann Cancer Res Ther 25(1), 38-39.
8. Takasu C, Yismaw WG, Kurita N, Yoshikawa K, Kashihara H, Kono T, Shimada M*. (2017) TU-100 exerts a protective effect against bacterial translocation by maintaining the tight junction. Surg Today. doi: 10.1007/s00595-017-1518-6. [Epub ahead of print]
9. Hasebe T, Matsukawa J, Ringus D, Miyoshi J, Hart J, Kaneko A, Yamamoto M, Kono T, Fujiya M, Kohgo Y, Wang C, Yuan C, Bissonette M, Musch M, Chang E. (2017) Daikenchuto (TU-100) Suppresses Tumor Development in the Azoxymethane and APCmin/+ Mouse Models of Experimental Colon Cance. Phytother Res. 31(1):90-99. doi: 10.1002/ptr.5735.
10. Nobutani K, Miyoshi J, Musch M, Nishiyama M, Watanabe J, Kaneko A, Yamamoto M, Yoshida M, Kono T, Jeong H, Chang E. (2017) Daikenchuto (TU-100) alters murine hepatic and intestinal drug metabolizing enzymes in an in vivo dietary model: effects of gender and withdrawal. Pharmacol Res Perspect. doi: 10.1002/prp2.361

2016年

1. Fujitsuka N., Asakawa A., Morinaga A., Amitani MS., Amitani H., Katsuura G., Sawada Y., Sudo Y., Uezono Y., Mochiki E., Sakata I., Sakai T., Hanazaki K., Yada T., Yakabi K., Sakuma E., Ueki T., Niijima A., Nakagawa K., Okubo N., Takeda H., Asaka M., Inui A. (2016). Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin1. Mol Psychiatry. 21:1613-1623.
2. Kawakubo K., Ohnishi S., Fujita H., Kuwatani M., Onishi R., Masamune A., Takeda H., Sakamoto N. (2016). Effect of Fetal Membrane-Derived Mesenchymal Stem Cell Transplantation in Rats With Acute and Chronic Pancreatitis. Pancreas. 45:707-713.
3. Hasebe T., Matsukawa J., Ringus D., Miyoshi J., Hart J., Kaneko A., Yamamoto M., Kono T., Fujiya M., Kohgo Y, Wang C, Yuan C, Bissonette M, Musch M, Chang E. (2016). Daikenchuto (TU-100) Suppresses Tumor Development in the Azoxymethane and APCmin/+ Mouse Models of Experimental Colon Cance. Phytother Res. doi: 10.1002/ptr.5735.
4. Hasebe T., Ueno N., Musch M., Nadimpalli A., Kaneko A., Kaifuchi N., Watanabe J., Yamamoto M., Inaba Y., Kono T., Fujiya M., Kohgo Y., Chang E. (2016). Daikenchuto (TU-100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K Pharmacology, Research & Perspectives. 4(1):e00215. doi: 10.1002/prp2.215.
5. Higashi D., Katsuno H., Kimura H., Takahashi K., Ikeuchi H., Kono T., Nezu R., Hatakeyama K., Kameyama H., Sasaki I., Fukushima K., Watanabe K., Kusunoki M., Araki T., Maeda K., Kameoka S., Itabashi M., Nakao S., Maeda K., Ohge H., Watadani Y., Watanabe T., Sunami E., Hotokezaka M., Sugita A., Funayama Y., Futami K. (2016). Current State of and Problems Related to Cancer of the Intestinal Tract Associated with Crohn's Disease in Japan. Anticancer Res. 36(7):3761-6.
6. Kono T., Fichera A., Maeda K., Sakai Y., Ohge H., Krane M., Katsuno H., Fujiya M. (2016). Kono-S anastomosis for surgical prophylaxis of anastomotic recurrence in Crohn's disease: an international multicenter study. J Gastrointest Surg. 20(4):783-790 doi: 10.1007/s11605-015-3061-3.
7. Kono T., Shimada M., Yamamoto M., Kase Y. (2016). Daikenchuto and GI Disorders Herbal Medicines, Springer, Editor Akio Inui (Chapter 12), 165-180.
8. Maejima T., Kono T., Orii F., Maemoto A., Furukawa S., Liming W., Kasai S., Fukahori S., Mukai N., Yoshikawa D., Karasaki H., Saito H., Nagashima K. (2016). Anal canal adenocarcinoma in a patient with long-standing Crohn’s disease arising from rectal mucosa that migrated from a previously treated rectovaginal fistula. Am J Case Rep. 17:448-453.
9. Matsuzaka S., Karasaki H., Ono Y., Ogata M., Oikawa K., Tamakawa S., Chiba S., Muraki M., Yokochi T., Funakoshi H., Kono T., Nagashima K., Mizukami Y. (2016). Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas. Pancreas. 45(6):915-918. doi: 10.1097/MPA.0000000000000556.
10. Mogami S., Sadakane C., Nahata M., Mizuhara Y., Yamada C., Hattori T., Takeda H. (2016). CRF receptor 1 antagonism and brain distribution of active components contribute to the ameliorative effect of rikkunshito on stress-induced anorexia. Sci Rep. 6: 27516.
11. Nozaki R., Kono T., Bochimoto H., Watanabe T., Oketani K., Sakamaki Y., Okubo N., Nakagawa K., Takeda H. (2016). Zanthoxylum fruit extract from Japanese pepper promotes autophagic cell death in cancer cells. Oncotarget. DOI:10.18632/oncotarget.11926.
12. Takeda H., Ohnishi S., Nakagawa K., Okubo N., Yamada C., Sadakane C., Saegusa Y., Nahata M., Hattori T. (2016). Rikkunshito and ghrelin. in Herbal Medicines: New Horizons (Methods in Pharmacology and Toxicology) , Humana Pres. pp135-180.
13. Tsuchiya K., Kubota K., Ohbuchi K., Kaneko A., Ohno N., Mase A., Matsushima H., Yamamoto M., Miyano K., Uezono Y., Kono T. (2016). Transient receptor potential ankyrin 1 (TRPA1) agonists improve intestinal transit in a murine model of postoperative ileus. Neurogastroenterol Motil. doi: 10.1111/nmo.12877.
14. Nakata S., Watanabe T., Nakagawa K., Takeda H., Ito A., Fujimuro M. (2016). The dynamics of histone H2A ubiquitination in HeLa cells exposed to rapamycin, ethanol, hydroxyurea, ER-stress, hydroxyurea, heat-shock and DNA damage. Biochem Biophys Res Commun. 2016 Feb 17. pii: S0006-291X(16)30246-7. doi: 10.1016/j.bbrc.2016.02.057.
15. Nakagawa K., Kohara T., Uehata Y., Miyakawa Y., Sato-Ueshima M., Okubo N., Asaka M., Takeda H., Kobayashi M. (2016). PIAS3 enhances the transcriptional activity of HIF-1α by increasing its protein stability. Biochem Biophys Res Commun. 469:470-476.
16. Shigemi Z., Furukawa Y., Hosokawa K., Minami S., Matsuhiro J., Nakata S., Watanabe T., Kagawa H., Nakagawa K., Takeda H., Fujimuro M. (2016). Diallyl trisulfide induces apoptosis by suppressing NF-κB signaling through destabilization of TRAF6 in primary effusion lymphoma. Int J Oncol. 48:293-304.
17. Watanabe A., Tanaka H., Sakurai Y., Tange K., Nakai Y., Ohkawara T., Takeda H., Harashima H., Akita H. (2016). Effect of particle size on their accumulation in an inflammatory lesion in a dextran sulfate sodium (DSS)-induced colitis model. Int J Pharm. 509:118-122.
18. Yada K., Ishibashi H., Mori H., Morine Y., Zhu C., Feng R., Kono T., Shimada M. (2016). Kampo medicine "Daikenchuto (TU-100)" prevents bacterial translocation and hepatic fibrosis in biliary atresia rat model. Surgery. 159(6):1600-1611. doi: 10.1016/j.surg.2016.02.002.

2015年

1. Hatakeyama H., Takahashi H., Oridate N., Kuramoto R., Fujiwara K., Homma A., Takeda H., Fukuda S. (2015). Hangeshashinto improves the completion rate of chemoradiotherapy and the nutritional status in patients with head and neck cancer. J Otorhinolaryngol Relat Spec.77(2):100-8.
2. Kono T., Fichera A., Maeda K., Sakai Y., Ohge H., Krane M., Katsuno H., Fujiya M. (2015). Kono-S anastomosis for surgical prophylaxis of anastomotic recurrence in Crohn's disease: an international multicenter study. J Gastrointest Surg. [Epub ahead of print]
3. Kono T., Fichera A. (2015). Recurrent CD:Surgical Prophylaxis-Kono-S anastomosis Crohn’s Disease: Basic Principles Editors: Fichera A., Krane M. (Eds.),227-236.
4. Kono T., Suzuki Y., Mizuno K., Miyagi C., Omiya Y., Sekine H., Mizuhara Y., Miyano K., Uezono Y. (2015). Preventive effect of oral goshajinkigan on chronic oxaliplatin-induced hypoesthesia in rats. Scientific Reports 5:16078.
5. Kono, T., M. Shimada, M. Yamamoto et al (2015). Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto. Front Pharmacol 6:159.
6. Katsuno H., Maeda K., Hanai T., Masumori K., Koide Y., Kono T. (2015) Novel antimesenteric functional end-to-end handsewn (Kono-S) anastomoses for Crohn's disease: a report of surgical procedure and short-term outcomes. Dig Surg. 32(1) 39-44.
7. Katsuno H., Maeda K., Kaiho T., Kunieda K., Funahashi K., Sakamoto J., Kono T., Hasegawa H., Furukawa Y., Imazu Y., Morita S., Watanabe M. (2015). Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multicenter, placebo-controlled study (JFMC39-0902). Jpn J Clin Oncol. 45(7) 650-6.
8. Kubota K., Ohtake N., Ohbuchi K., Mase A., Imamura S., Sudo Y., Miyano K., Yamamoto M., Kono T., Uezono Y.. (2015). Hydroxy-α sanshool induces colonic motor activity in rat proximal colon: a possible involvement of KCNK9.Am J Physiol Gastrointest Liver Physiol. 308(7) 579-90.
9. Maehara O., Sato F., Natsuizaka M., Asano A., Kubota Y., Itoh J., Tsunematsu S., Terashita K., Tsukuda Y., Nakai M., Sho T., Suda G., Morikawa K., Ogawa K., Chuma M., Nakagawa K., Ohnishi S., Komatsu Y., Whelan K.A., Nakagawa H., Takeda H., Sakamoto N. (2015). A pivotal role of Kruppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. Cancer Biol Ther, 16:1453-1461.
10. Matsuda C., Munemoto Y., Mishima H., Nagata N., Oshiro M., Kataoka M., Sakamoto J., Aoyama T., Morita S., Kono T.(2015). Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol. 2015 76(1) 97-103.
11. Nishimura M., Yoshida S., Haramoto M., Mizuno H., Fukuda T., Kagami-Katsuyama H., Tanaka A., Ohkawara T., Sato Y., Nishihira J.(2015). Effects of white rice containing enriched gamma-aminobutyric acid on blood pressure. J Tradit Complement Med. 6(1):66-71.
12. Nishimura M., Ohkawara T., Kanayama T., Kitagawa K., Nishimura H., Nishihira J.(2015).Effects of the extract from roasted chicory (Cichorium intybus L.) root containing inulin-type fructans on blood glucose, lipid metabolism, and fecal properties. J Tradit Complement Med. 5(3):161-7.
13. Onishi R., Ohnishi S., Higashi R., Watari M., Yamahara K., Okubo N., Nakagawa K., Katsurada T., Suda G., Natsuizaka M., Takeda H., Sakamoto N. (2015). Human Amnion-Derived Mesenchymal Stem Cell Transplantation Ameliorates Dextran Sulfate Sodium-Induced Severe Colitis in Rats. Cell Transplant. [Epub ahead of print]
14. Ono M., Ohnishi S., Honda M., Ishikawa M., Hosono H., Onishi R., Nakagawa K., Takeda H., Sakamoto N. (2015). Effects of human amnion-derived mesenchymal stromal cell transplantation in rats with radiation proctitis. Cytotherapy, 17:1545-1559.
15. Oki E., Emi Y., Kojima H., Higashijima J., Kato T., Miyake Y., Kon M., Ogata Y., Takahashi K., Ishida H., Saeki H., Sakaguchi Y., Yamanaka T., Kono T., Tomita N., Baba H., Shirabe K., Kakeji Y., Maehara Y. (2015) Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol. 20(4) 767-75.
16. Ohnishi S., Takeda H. (2015). Herbal medicines for the treatment of cancer chemotherapy-induced side effects. Front Pharmacol. 10;6:14. doi: 10.3389/fphar.2015.0001
17. Saegusa Y., Hattori T., Nahata M., Yamada C., Takeda H. (2015). A New Strategy Using Rikkunshito to Treat Anorexia and Gastrointestinal Dysfunction. Evid Based Complement Alternat Med. 2015;2015:364260. doi: 10.1155/2015/364260.
18. Suzuki T., Kono T., Bochimoto H., Hira Y., Watanabe T., Furukawa H. (2015). An injured tissue affects the opposite intact peritoneum during postoperative adhesion formation. Scientific Reports 8;5:7668.
19. Sadakane C., Watanabe J., Fukutake M., Nisimura H., Maemura K., Kase Y., Kono T. (2015). Pharmacokinetic Profiles of Active Components After Oral Administration of a Kampo Medicine, Shakuyakukanzoto, to Healthy Adult Japanese Volunteers. Pharm Sci. 104(11) 3952-9.
20. Matsuzaka S., Karasaki H., Ono Y., Ogata M., Oikawa K., Tamakawa S., Chiba S., Muraki M., Yokochi T., Funakoshi H., Kono T., Nagashima K.,Mizukami Y. (2015) Tracking the clonal evolution of adenosquamous carcinoma, a rare variant of intraductal papillary mucinous neoplasm of the pancreas. Pancreas (in press).
21. Yamada C., Saegusa Y., Nahata M., Sadakane C., Hattori T., Takeda H. (2015) Influence of Aging and Gender Differences on Feeding Behavior and Ghrelin-Related Factors during Social Isolation in Mice. PLoS One. 10(10):e0140094.
22. Yamada C., Sadakane C., Nahata M., Saegusa Y., Nakagawa K., Okubo N., Ohnishi S., Hattori T., Takeda H. (2015). Serotonin 2C receptor contributes to gender differences in stress-induced hypophagia in aged mice. Psychoneuroendocrinology. 55:81-93.
23. Yamasaki K., Zhao S., Nishimura M., Zhao Y., Yu W., Shimizu Y., Nishijima K., Tamaki N., Takeda H., Kuge Y. (2015). Radiolabeled BMIPP for Imaging Hepatic Fatty Acid Metabolism: Evaluation of Hepatic Distribution and Metabolism in Mice at Various Metabolic Statuses Induced by Fasting in Comparison with Palmitic Acid. Mol Imaging. 14:1-11.
24. Yoshimura A., Ohnishi S., Orito C., Kawahara Y., Takasaki H., Takeda H., Sakamoto N., Hashino S. (2015). Association of peripheral total and differential leukocyte counts with obesity-related complications in young adults. Obes Facts. 8:1-16.
25. Watanabe J., Kaifuchi N., Kushida H., Matsumoto T., Fukutake M., Nishiyama M., Yamamoto M., Kono T.(2015). Intestinal, portal, and peripheral profiles of daikenchuto (TU-100)'s active ingredients after oral administration. Pharmacol Res Perspect. 3(5) e00165.

2014年

1. Aomatsu E., Takahashi N., Sawada S., Okubo N., Hasegawa T., Taira M., Miura H., Ishisaki A., Chosa N. (2014). Novel SCRG1/BST1 axis regulates self-renewal, migration, and osteogenic differentiation potential in mesenchymal stem cells. SCIENTIFIC REPORTS. 4:3652 doi:10.1038/srep03652
2. Aoyama T., Nishikawa K., Takiguchi N., Tanabe K., Imano M., Fukushima R., Sakamoto J., Oba M.S., Morita S., Kono T., Tsuburaya A. (2014). Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol. 73(5):1047-1054.
3. Chiba T., Hosono H., Nakagawa K., Asaka M., Takeda H., Matsuda A., Ichikawa S. (2014). Total synthesis of syringolin A and improvement of its biological activity. Angew Chem Int Ed Engl. 53:4836-4839.
4. Hanamatsu H., Ohnishi S., Sakai S., Yuyama K., Mitsutake S., Takeda H., Hashino S., Igarashi Y. (2014). Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults. Nutr Diabetes. 4:e141. doi: 10.1038/nutd.2014.38.
5. Hayakawa M., Ono Y., Wada T., Yanagida Y., Sawamura A., Takeda H., Gando S. (2014). Effects of Rikkunshito (traditional Japanese medicine) on enteral feeding and the plasma ghrelin level in critically ill patients: a pilot study. J Intensive Care. 2:53. doi: 10.1186/s40560-014-0053-4.
6. Katayama K., Okamura T., Sunadome T., Nakagawa K., Takeda H., Shiro M., Matsuda A., Ichikawa S. (2014). Synthesis and biological evaluation of quinaldopeptin. J Org Chem. 79:2580-2590.
7. Katayama K., Nakagawa K., Takeda H., Matsuda A., Ichikawa S. (2014). Total synthesis of sandramycin and its analogues via a multicomponent assemblage. Org Lett. 16:428-431.
8. Kono T., Takeda H., Shimada M., Kase Y., Uezono Y. (2014). Novel therapeutics for adverse effects of antitumor therapy: the promise of multicomponent, traditional Japanese herbal remedies. J Carcinog Mutagen. Feb 25, [Epub ahead of print]　doi.org/10.4172/2157-2518.S8-007
9. Kono T., Kaneko A., Matsumoto C., Miyagi C., Ohbuchi K., Mizuhara Y., Miyano K., Uezono Y. (2014). Multitargeted Effects of Hangeshashinto for Treatment of Chemotherapy- Induced Oral Mucositis on Inducible Prostaglandin E2 Production in Human Oral Keratinocytes. Integr Cancer Ther. 13(5):435-445.
10. Kono T., Fichera A. (2014). Kono-S anastomosis for Crohn’s disease. Colorectal Disease. 16(10):833, doi:10.1111/codi.12722
11. Mizuno K., Kono T., Suzuki Y., Miyagi C., Omiya Y., Miyano K., Kase Y., Uezono Y. (2014). Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat. J Pharmacol Sci. 125(1):91-98.
12. Nahata M., Saegusa Y., Sadakane C., Yamada C., Nakagawa K., Okubo N., Ohnishi S., Hattori T., Sakamoto N., Takeda H. (2014). Administration of exogenous acylated ghrelin or rikkunshito, an endogenous ghrelin enhancer, improves the decrease in postprandial gastric motility in an acute restraint stress mouse model. Neurogastroenterol Motil. 26:821-831.
13. Nishimura M., Ohkawara T., Sato H., Takeda H., Nishihira J. (2014). Pumpkin Seed Oil Extracted From Cucurbita maxima Improves Urinary Disorder in Human Overactive Bladder. J Tradit Complement Med. 4:72-74.
14. Nishimura M., Ohkawara T., Kagami-Katsuyama H., Sekiguchi S., Taira T., Tsukada M., Shibata H., Nishihira J. (2014). Alteration of intestinal flora by the intake of enzymatic degradation products of adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) with improvement of skin condition. J Functional Foods. 7:487-494.
15. Sakata Y., Tominaga K., Kato M., Takeda H., Shimoyama Y., Takeuchi T., Iwakiri R., Furuta K., Sakurai K., Odaka T., Kusunoki H., Nagahara A., Iwakiri K., Furuta T., Murakami K., Miwa H., Kinoshita Y., Haruma K., Takahashi S., Watanabe S., Higuchi K., Fujimoto K., Kusano M., Arakawa T; G-PRIDE study group. (2014). Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito. BMC Gastroenterol. 14:116. doi: 10.1186/1471-230X-14-116.
16. Shimada M., Morine Y., Nagano H., Hatano E., Kaiho T., Miyazaki M., Kono T., Kamiyama T., Morita S., Sakamoto J., Kusano M., Saji S., Kanematsu T., Kitajima M. (2014). Effect of TU-100, a traditional Japanese medicine, administered after Hepatic Resection in Patients with Liver Cancer: a multi-center, randomized, double-blind, placebo-controlled phase III trial (JFMC40-1001). Int J Clin Oncol. 73(5):1047-1054.
17. Ueno N., Hasebe T., Kaneko A., Yamamoto M., Fujiya M., Kohgo Y., Kono T., Wang C.Z., Yuan C.S., Bissonnette M., Chang E.B., Musch M.W. (2014). TU-100 (daikenchuto) and ginger ameliorate anti-CD3 antibody induced T cell-mediated murine enteritis: microbe-independent effects involving Akt and NF-κB suppression. PloS ONE. 23;9(5):e97456. 2014 doi:10.1371/journal.pone.0097456
18. Watanabe K., Karasaki H., Mizukami Y., Kawamoto T., Kono T., Imai K., Einama T., Taniguchi M., Kohgo Y., Furukawa H. (2014). Cyst infection of intraductal papillary mucinous neoplasms of the pancreas: management of a rare complication: report of 2 cases. Pancreas. 43(3):478-81.
19. Yokota J., Chosa N., Sawada S., Okubo N., Takahashi N., Hasegawa T., Kondo H., Ishisaki A. (2014). PDGF-induced PI3K-mediated signaling enhances the TGF-β-induced osteogenic differentiation of human mesenchymal stem cells in a TGF-β-activated MEK-dependent manner. International Journal of Molecular Medicine. 33:534-542 doi: 10.3892/ijmm.2013.1606

2013年

1. Hattori T., Yakabi K., Takeda H. (2013). Cisplatin-induced anorexia and ghrelin. Vitam Horm. 92:301-317.
2. Hata T., Kato M., Kudo T., Nishida M., Nishida U., Imai A., Yoshida T., Hirota J., Kamada G., Ono S., Nakagawa M., Nakagawa S., Shimizu Y., Takeda H., Asaka M. (2013). Comparison of Gastric Relaxation and Sensory Functions between Functional Dyspepsia and Healthy Subjects Using Novel Drinking-Ultrasonography Test. Digestion. 87:34-39.
3. Nahata M., Muto S., Nakagawa K., Ohnishi S., Sadakane C., Saegusa Y., Iizuka S., Hattori T., Asaka M., Takeda H. (2013). Serotonin 2C receptor antagonism ameliorates novelty-induced hypophagia in aged mice. Psychoneuroendocrinology. 38:2051-2064.
4. Nahata M., Saegusa Y., Harada Y., Tsuchiya N., Hattori T., Takeda H. (2013). Changes in ghrelin-related factors in gastroesophageal reflux disease in rats. Gastroenterology Research and Practice: 50481.
5. Ohnishi S., Maehara O., Nakagawa K., Kameya A., Otaki K., Fujita H., Higashi R., Takagi K., Asaka M., Sakamoto N., Kobayashi M., Takeda H. (2013). Hypoxia-inducible Factors Activate CD133 Promoter through ETS Family Transcription Factors. PLoS ONE: 8: e66255.
6. Goudarzi H., Iizasa H., Furuhashi M., Nakazawa S., Nakane R., Liang S., Hida Y., Yanagihara K., Kubo T., Nakagawa K., Kobayashi M., Irimura T., Hamada J.I. (2013). Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1α-MUC1 pathway. Cancer Lett. 39:82-92.
7. Tominaga K., Kato M., Takeda H., Shimoyama Y., Umegaki E., Iwakiri R., Furuta K., Sakurai K., Odaka T., Kusunoki H., Nagahara A., Iwakiri K., Furuta T., Murakami M., Miwa H., Kinoshita Y., Haruma K., Takahashi S., Watanabe S., Higuchi K., Kusano M,, Fujimoto K., Arakawa T., and the G-PRIDEstudy group. (2013). A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study. J Gastroenterol. 49(10):1392-1405
8. Yamada C., Saegusa Y., Nakagawa K., Ohnishi S., Muto S., Nahata M., Sadakane C., Hattori T., Sakamoto N., Takeda H. (2013). Rikkunshito, a Japanese Kampo Medicine, Ameliorates Decreased Feeding Behavior via Ghrelin and Serotonin 2B Receptor Signaling in a Novelty Stress Murine Model. BioMed Reasarch International. 792940.
9. Takeda H., Nakagawa K., Okubo N., Nishimura M., Muto S., Ohnishi S., Sakamoto N., Hosono H., Asaka M. (2013). Pathophysiologic Basis of Anorexia: Focus on the Interaction between Ghrelin Dynamics and the Serotonergic System. Biol Pharm Bull. 36:1401-1405.
10. Kono T., Kaneko A., Omiya Y., Ohbuchi K., Ohno N., Yamamoto M. (2013). Epithelial transient receptor potential ankyrin 1 (TRPA1)-dependent adrenomedullin upregulates blood flow in rat small intestine. Am J Physiol Gastrointest Liver Physiol. 304:G428-G436.
11. Munekage M., Ichikawa K., Kitagawa H., Uehara H., Watanabe J., Kono T., Hanazaki K. (2013). Population Pharmacokinetic Analysis of Daikenchuto, a Traditional Japanese Medicine (Kampo) in Japanese and US Health Volunteers. Drug Metab Dispos. 41:1256-1263.
12. Nishimura M., Ohkawara T., Kagami-Katsuyama H., Sato H., Nishihira J. (2013). Improvement of Blood Pressure, Glucose Metabolism, and Lipid Profile by the Intake of Powdered Asparagus ( Lu Sun) Bottom-stems and Cladophylls. J Tradit Complement Med. 3(4):250-5. doi: 10.4103/2225-4110.119728.
13. Kono T., Hata T., Morita S., Munemoto Y., Matsui T., Kojima H., Takemoto H., Fukunaga M., Nagata N., Shimada M., Sakamoto J., Mishima H. (2013). Goshajinkigan Oxaliplatin Neurotoxicity Evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemotherapy and Pharmacology. 72:1283-1290.
14. Kono T., Kaneko A., Matsumoto C., Miyagi C., Ohbuchi K., Mizuhara Y., Miyano K., Uezono Y. (2013). Multitargeted effects of hangeshashinto for treatment of chemotherapy-induced oral mucositis on inducible PGE2 production in human oral keratinocytes. Integrative Cancer Therapies. doi: 10.1177/1534735413520035.
15. Kaneko A., Kono T., Miura N., Tsuchiya N., Yamamoto M. (2013). Preventive effect of TU-100 on a type-2 model of colitis in mice: Possible involvement of enhancing adrenomedullin in intestinal epithelial cells. Gastroenterology Research and Practice. doi:10.1155/2013/384057.
16. Sakatani A., Fujiya M., Ito T., Inaba Y., Ueno N., Kashima S., Tominaga M., Moriichi K., Okamoto K., Tanabe H., Ikuta K., Ohtake T., Kono T., Furukawa H., Ashida T., Kohgo Y. (2013). Infliximab extends the duration until the first surgery in patients with Crohn’s disease. BioMed Research International. 879491.
17. Abe T., Kono T., Hachiro Y., Kunimoto M., Furukawa H. (2013). Risk factors for internal anal sphincter dysfunction in Japanese adults. Open J Gastroenterology. 3:25-34.
18. Kimura H.*, Okubo N.*(1st co-author), Chosa N., Kyakumoto S., Kamo M., Miura H., Ishisaki A. (2013). EGF positively regulates the proliferation and migration, and negatively regulates the myofibroblast differentiation of periodontal ligament-derived endothelial progenitor cells through MEK/ERK- and JNK-dependent signals. Cellular Physiology and Biochemistry. 32(4):899-914
19. Saito D., Kyakumoto S., Chosa N., Ibi M., Takahashi N., Okubo N., Sawada S., Ishisaki A., Kamo M. (2013). Transforming growth factor-β1 induces epithelial-mesenchymal transition and integrin α3β1-mediated cell migration of HSC-4 human squamous cell carcinoma cells through Slug. The Journal of biochemistry, 153(3):303-15. doi: 10.1093/jb/mvs144.

2012年

1. Takeda H., Muto S., Nakagawa K., Ohnishi S., Asaka M. (2012). Rikkunshito and ghrelin secretion. Curr Pharm Des. 18:4827-4838.
2. Takeda H., Muto S., Nakagawa K., Ohnishi S., Sadakane C., Saegusa Y., Nahata M., Hattori T., Asaka M. (2012). Rikkunshito as a ghrelin enhancer. Methods Enzymol. 514:333-351.
3. Nakagawa K., Uehata Y., Natsuizaka M., Kohara T., Darmanin S., Asaka M., Takeda H., Kobayashi M. (2012). The nuclear protein Artemis promotes AMPK activation by stabilizing the LKB1-AMPK complex. Biochem. Biophys. Res. Commun. 427:790-795.
4. Naka T., Ide S., Nakako T., Hirata M., Majima Y., Deyama S., Takeda H., Yoshioka M., Minami M. (2012). Activation of β-adrenoceptors in the bed nucleus of the stria terminalis induces food intake reduction and anxiety-like behaviors. Neuropharmacology. 67:326-330.
5. Katsurada T., Kobayashi W., Tomaru U., Baba T., Furukawa S., Ishizu A., Takeda K., Sakamoto N., Asaka M., Takeda H., Kasahara M. (2012). Decrease of peripheral and intestinal NKG2A-positive T cells in patients with ulcerative colitis. PLoS ONE 7: e44113.
6. Takedatsu H., Mitsuyama K., Mochizuki S., Kobayashi T., Sakurai K., Takeda H., Fujiyama Y., Koyama Y., Nishihira J., Sata M. (2012). A new therapeutic approach using a schizophyllan-based drug delivery system for inflammatory bowel disease. Mol Ther. 20:1234-1241.
7. Imai A., Kato M., Ono S., Shimizu Y., Takeda H., Asaka M. (2012). Efficacy of carbon dioxide-insufflating colonoscopy in patients with irritable bowel syndrome (IBS): a randomized double-blind study. J Gastroenterol Hepatol. 27:1623-1628.
8. Nahata M., Muto S., Oridate N., Ohnishi S., Nakagawa K., Sadakane C., Saegusa Y., Hattori T., Asaka M., Takeda H. (2012). Impaired ghrelin signaling is associated with gastrointestinal dysmotility in rats with gastroesophageal reflux disease. Am J Physiol Gastrointest Liver Physiol. 303:G42-53.
9. Sasajima H., Nakagawa K., Kashiwayanagi M., Yokosawa H. (2012). Polyubiquitination of the B-Cell Translocation Gene 1 and 2 Proteins Is Promoted by the SCF Ubiquitin Ligase Complex Containing betaTrCP. Biol. Pharm. Bull. 35:1539-1545.
10. Kono T., Asama T., Chisato N., Ebisawa Y., Okayama T., Imai K., Karasaki H., Furukawa H., Yoneda M. (2012). Polaprezinc prevents ongoing thioacetamide-induced liver fibrosis in rats. Life Sciences. 90:122-130.
11. Kono T., Satomi M., Suno M., Kimura, N., Yamazaki, Furukawa H., Matsubara K. (2012). Oxaliplatin- induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation. Brain and Behavior. 2:68-73.
12. Fischera A., Zoccali M., Kono T. (2012). Antimesenteric functional end-to-end handsewn (Kono-S) anastomosis. J of Gastrointestinal Surgery. 16:1412-1416.
13. Ito T., Tanabe H., Ayabe T., Ishikawa C., Inaba Y., Maemoto A., Kono T., Ashida T., Fujiya M., Kohgo Y. (2012). Paneth cells regulate both chemotaxis of immature dendritic cells and cytokine production from epithelial cells. Tohoku J Exp Med. 227:39-48.
14. Nozaki R., Tamura S., Ito A., Moriyama T., Yamaguchi K., Kono T. (2012). A rapid method to isolate soluble royal jelly proteins. Food Chemistry. 134:2332-2337.

2011年

1. Sadakane C., Muto S., Nakagawa K., Ohnishi S., Saegusa Y., Nahata M., Hattori T., Asaka M., Takeda H. (2011). 10-Gingerol, a component of rikkunshito, improves cisplatin-induced anorexia by inhibiting acylated ghrelin degradation. Biochem Biophys Res Commun. 412:506-511.
2. Saegusa Y., Takeda H., Muto S., Nakagawa K., Ohnishi S., Sadakane C., Nahata M., Hattori T., Asaka M. (2011). Decreased plasma ghrelin contributes to anorexia following novelty stress. Am J Physiol Endocrinol Metab. 301:E685-696.
3. Saegusa Y., Takeda H., Muto S., Oridate N., Nakagawa K., Sadakane C., Nahata M., Harada Y., Iizuka M., Hattori T., Asaka M. (2011). Decreased motility of the lower esophageal sphincter in a rat model of gastroesophageal reflux disease may be mediated by reductions of serotonin and acetylcholine signaling. Biol Pharm Bull. 34:704-711.
4. Ohkawara T., Takeda H., Ohnishi S., Kato M., Nishihira J., Asaka M. (2011). Macrophage migration inhibitory factor contributes to development of nonsteroidal anti-inflammatory drugs-induced gastric injury in mice. Int Immunopharmacol. 11:418-423.
5. Sadakane C., Kase Y., Koseki J., Hasegawa Y., Shindo S., Maruyama H., Takeda S., Takeda H., Hattori T. (2011). Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats. Clin Exp Nephrol. 15:14-24.
6. Ohkawara T., Koyama Y., Onodera S., Takeda H., Kato M., Asaka M., Nishihira J. (2011). DNA vaccination targeting macrophage migration inhibitory factor prevents murine experimental colitis. Clin Exp Immunol. 163:113-122.
7. Hassan N.M., Hamada J., Kameyama T., Tada M., Nakagawa K., Yoshida S., Kashiwazaki H., Yamazaki Y., Suzuki Y., Sasaki A., Nagatsuka H., Inoue N., Moriuchi T. (2011). Increased expression of the PRL-3 Gene in Human Oral Squamous Cell Carcinoma and Dysplasia Tissues. Asian Pac J Cancer Prev. 2:947-951.

2010年

1. Takeda H., Muto S., Hattori T., Sadakane C., Tsuchiya K., Katsurada T., Ohkawara T., Oridate N., Asaka M. (2010). Rikkunshito ameliorates the aging-associated decrease in ghrelin receptor reactivity via phosphodiesterase III inhibition. Endocrinology. 151:244-252.
2. Sadakane C., Koseki J., Inagaki Y., Hasegawa Y., Shindo S., Maruyama H., Takeda S., Takeda H., Hattori T. (2010). TJN-419 improves dextran sulfate sodium-induced colitis via inhibition of interleukin-12 release. Biol Pharm Bull. 33:84-90.
3. Saegusa Y., Sadakane C., Koseki J., Hasegawa Y., Shindo S., Takeda S., Takeda H., Hattori T. (2010). (E)-N- [(3,4-dimethoxyphenethyl)] -N- methyl- 3- (3-pyridyl)-2-propenamide (TJN-331) inhibits mesangial expansion in experimental IgA nephropathy in ddY mice. Clin Exp Nephrol. 14:528-535.
4. Saegusa Y., Sadakane C., Koseki J., Hasegawa Y., Shindo S., Maruyama H., Kase Y., Takeda S., Takeda H., Hattori T. (2010). Effect of TJN-331 on anti-Thy1 nephritis in rats via inhibition of transforming growth factor-β1 production. Biol Pharm Bull. 33:1710-1715.
5. Saegusa Y., Sadakane C., Koseki J., Hasegawa Y., Shindo S., Maruyama H., Takeda S., Takeda H., Hattori T. (2010). TJN-331 improves anti-glomerular basement membrane nephritis by inhibiting the production of intraglomerular transforming growth factor-beta1. Biol Pharm Bull. 33:1349-1354.
6. Kinoshita K., Nakagawa K., Hamada J., Hida Y., Tada, M., Kondo, S., and Moriuchi T. (2010). Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. Int J Oncol. 37:869-877.
7. Tsuchiya K., Hida K., Hida, Y., Muraki C., Ohga N., Akino T., Kondo T., Miseki T., Nakagawa K., Shindoh M., et al. (2010). Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. Int J Oncol. 36:1379-1386.
8. Yoshikawa K., Hamada J., Tada M., Kameyama T., Nakagawa K., Suzuki Y., Ikawa M., Hassan N.M., Kitagawa Y., and Moriuchi T. (2010). Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomed Res. 31:401-411.

2009年

1. Ono S., Kato M., Imai A., Yoshida T., Hirota J., Hata T., Takagi K., Kamada G., Ono Y., Nakagawa M., Nakagawa S., Shimizu Y., Takeda H., Asaka M. (2009). Preliminary trial of rebamipide forprevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Biochem Nutr. 45:248-253.
2. Sadakane C., Hattori T., Koseki J., Inagaki Y., Hasegawa Y., Shindo S., Takeda S., Takeda H. (2009). TJN-259 improves mesangial lesions in experimental immunoglobulin anephropathy in ddY mice. Biol Pharm Bull. 32:1728-1733.
3. Nakajima S., Niizeki H., Tada M., Nakagawa K., Kondo S., Okada F., and Kobayashi M. (2009). Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231. Oncol Rep. 22:143-148.

2008年

1. Takeda H., Sadakane C., Hattori T., Katsurada T., Ohkawara T., Nagai K., Asaka M. (2008). Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology. 134:2004-2013.
2. Oridate N., Takeda H., Mesuda Y., Nishizawa N., Furuta Y., Asaka M., Fukuda S. (2008). Evaluation of upper abdominal symptoms using the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease in patients with laryngopharyngeal reflux symptoms. J. Gastroenterol. 43:519-523.
3. Ohkawara T., Mitsuyama K., Takeda H., Asaka M., Fujiyama Y., Nishihira J. (2008). Lack of macrophage migration inhibitory factor suppresses innate immune response in murine dextran sulfate sodium-induced colitis. Scand. J. Gastroenterol. 43:1497-1504.

2018年

1. 河野　透　末梢神経障害　副作用への漢方薬活用術　薬局 69(2), 47-52, 2018
2. 河野　透　半夏瀉心湯　漢方薬　病棟で使う順　ザ・ベストテン　月間薬事 60(3), 41-48, 2018

2017年

1. 武田 宏司 (2017) 　フレイルに対する漢方医学的アプローチ：消化器におけるフレイルと漢方 - 食欲不振　 Progress in Medicine 37: 181-185.
2. 武田 宏司 (2017) 　消化管ホルモン　プリンシプル消化器疾患の臨床1　食道・胃・十二指腸の診療アップデート　中山書店 50-53, 69-72.
3. 野崎 怜雄、河野 透、武田 宏司 (2017) 　生薬薬理と漢方ー山椒　漢方と最新治療　漢方と最新治療 26: 285-292.
4. 武田 宏司, 藤塚 直樹, 服部 智久, 乾 明夫 (2017) 　漢方とアンチエイジング：六君子湯の作用 - グレリンを含めて　アンチ・エイジング医学 13: 790-795.

2016年

1. 武田 宏司 (2016) 脳腸相関にかかわる生理活性物質-セロトニン. 臨床栄養 128:747-753.
2. 武田 宏司 (2016) 六君子湯のグレリンを介する食欲改善作用. 漢方医学 40:156-159.
3. 屋嘉比 康治, 上園 保仁, 乾 明夫, 武田 宏司 (2016) グレリンと六君子湯. 漢方医学 40:124-135.
4. 桂田 武彦, 武田 宏司 (2016) ステロイド製剤のラインナップ充実によるIBD治療のこれから-クローン病の治療. 消化器の臨床 19:444-448.
5. 武田 宏司 (2016) 食欲異常と消化管-老化と食欲. 臨床消化器内科 31:1261-1267.
6. 武田 宏司 (2016) 下痢　内科診断学（第３版). 医学書院 576-584.
7. 武田 宏司 (2016) 便秘　内科診断学（第３版). 医学書院 585-590.
8. 河野 透, 前島 拓, 笠井 章次, 向井 伸貴, 深堀 晋, 吉川大太郎, 王 利明, 唐崎 秀則 (2016) クローン病に対する外科手術 INTESTINE 20(2), 165-172.
9. 河野 透, アレサンドロ フィケラ (2016) Crohn病の手術　外科的再狭窄予防法（Kono-S吻合）消化器外科 39(5), 604-609.
10. 河野 透 (2016) 大建中湯の作用メカニズム　腸管の運動促進作用と血流増加作用.漢方医学 40(2), 81-84.
11. 河野 透 (2016) 抗がん剤の神経障害に対する漢方薬. メビオ 33(2),18-30.

2015年

1. 武田 宏司 (2015) 六君子湯. 脳21　18:317-321.
2. 武田 宏司 (2015) 機能性消化管疾患と漢方薬治療. 臨床消化器内科　30:257-262.
3. 武田 宏司, 武藤 修一, 大西 俊介 (2015) シスプラチンの副作用に対するKampoのメカニズム. 医薬ジャーナル　51:75-80.
4. 河野 透 (2015) 消化器外科Crohn病に対する外科治療.Annual Review消化器　2015巻､233-240.
5. 河野 透 (2015) 抗がん剤の副作用に対するKampoのエビデンス. 医薬ジャーナル 51(2), 669-703.
6. 河野 透 (2015) 使ってみよう漢方薬. 外科と漢方　98-1061.
7. 宮野 加奈子, 河野 透, 上園 保仁 (2015) 抗がん剤治療による口内炎に対する半夏瀉心湯の効果. 日本薬理学雑誌146（2）76-80.

2014年

1. 武田 宏司 (2014) 脳腸相関からみた六君子湯の食欲改善作用. 日本東洋心身医学研究　29:16-20.
2. 中川 宏治, 武田 宏司 (2014) 医学用語解説　脱アセチル化酵素SIRT7　G.I.Research　22:373-375.
3. 大久保 直登, 中川 宏治, 武田 宏司 (2014) 咀嚼(mastication)と歯根膜幹細胞(periodontal ligament stem cell. G.I.Research　22:370-372.
4. 武田 宏司 (2014) 機能性ディスペプシアと過敏性腸症候群における漢方薬の使いかた. Medical Practice 31:1329-1333.
5. 武田 宏司 (2014) 各種の生体反応異常としての機能性ディスペプシア. 日本消化器病学会雑誌　111:1058-1070.
6. 武田 宏司 (2014) 機能性ディスペプシア. 医学と薬学　71:805-810.
7. 河野 透, 前田 耕太郎, 坂井 義治, 大毛 宏喜, 島田 光生, アレサンドロ フィケラ, ファブリッチオ ミケラッシー (2014) Crohn病に対する外科治療　切除吻合法（手縫い吻合vs器械吻合）　Kono-S吻合　外科　76(3):267-273.
8. 河野 透, 笠井 章次, 北川 真吾 (2014) 炎症性腸疾患の手術. 消化器病診療（第２版）、医学書院、日本消化器病学会監修, 397-400.
9. 河野 透 (2014) 消化器疾患と漢方薬. 炎症性腸疾患　医学と薬学 71(5):823-829.
10. 河野 透 (2014) 日本における伝統薬によるがん治療の現状−外科的見地から. 日中医学 28(4):14-20.
11. 河野 透 (2014) 便通異常. 腫瘍内科 14(2):128-135.

2013年

1. 武田 宏司, 中川 宏治, 西村 三恵, 大久保 直登, 細野 秀崇, 浅香 正博, 武藤 修一, 大西 俊介, 坂本 直哉 (2013) 六君子湯による摂食不振・悪液質の改善. G.I.Research　21:48-58.
2. 武田 宏司, 武藤 修一, 大西 俊介 (2013) 消化管疾患に対する漢方医療の実際　消化器癌に対する補助療法　食欲不振. 臨床消化器内科　28:209-214.
3. 武田 宏司, 河野 透 (2013) IBSに対して漢方薬をどう使うか. 消化器の臨床　16:63-67.
4. 武田 宏司, 武藤 修一, 大西 俊介, 河野 透 (2013) 抗癌剤にともなうcachexiaとその治療. 栄養-評価と治療　30 (4):1-5.
5. 河野 透, 武田 宏司, 上園 保仁 (2013) 外科医のためのKampo EBM UP TO DATE　6. 抗癌剤の副作用と漢方薬　日本外科学会雑誌 114:251-255.
6. 河野 透, 武田 宏司, 上園 保仁, 島田 光生 (2013) 消化器外科と漢方. 消化器外科　36:1299-1305.
7. 河野 透, 上園 保仁, 武田 宏司, 笠井 章次, 佐藤 宏彦, 島田 光生 (2013) オキサリプラチンによるしびれ- 牛車腎気丸. 臨床外科 12:1319-1323.
8. 武田 宏司 (2013) 便秘. 今日の治療と看護（改訂第3版）南江堂　121-124.
9. 武田 宏司, 浅香 正博 (2013) 消化器内科（腸管）　内科医のための薬の禁忌100（第２版）　医学書院 61-91.
10. 武田 宏司 (2013) 消化管ホルモン. 消化器病学　基礎と臨床　西村書店　133-138.
11. 河野 透, 前田 耕太郎, 坂井 義治, 大毛 宏喜, 島田 光生, Alessandro Fichera (2013) 腸管切除再建法：機能的端端手縫い吻合法（Kono-S吻合）手術67:1259-1266.
12. 河野 透, 前田 耕太郎, 坂井 義治, 大毛 宏喜, Alessandro Fichera (2013) 新しい腸管吻合法：Kono-S吻合　著書名：炎症性腸疾患の外科治療 メジカルビュー社 139-145.
13. 河野 透 (2013) Crohn病の腸管病変に対する手術適応と術式の選択　消化器外科 36:65-76.

2012年

1. 武田 宏司 (2012) 過敏性腸症候群の診かた. 治療　漢方療法　治療　94:375-379.
2. 武田 宏司, 武藤 修一, 大西 俊介 (2012) こんな時には漢方薬　方剤単位で学ぶ「漢方薬」提案のヒント　六君子湯　薬局　6:3290-3299.
3. 河野 透, 岡本 耕太郎, 高後 裕 (2012) Crohn病腸管手術の新たな標準術式となる可能性と現状：Kono-S吻合消化器内視鏡　24:251-257.
4. 河野 透, 上園 保仁 (2012) 腸管血流からみた大建中湯の役割　アメリカ臨床治験薬TU-100になった理由 医学のあゆみ　241:163-169.
5. 河野 透, 高後 裕, ｱﾚｻﾝﾄﾞﾛﾌｨｹﾗ, 大毛 宏喜, 坂井 義治, 前田 耕太郎 (2012) 達人こだわりの手術テクニック 手術　65:1355-1360.
6. 河野 透, 海老澤 良昭, 千里 直之, 北川 真吾, 古川 博之 (2012) 炎症性腸疾患における機能温存手術の適応と限界 北海道外科雑誌　57: 20-25.
7. 河野 透 (2012) 今日のがん治療を支える漢方薬のエビデンス　著書名：がん漢方　南山堂　16-25.
8. 掛地 吉弘, 河野 透 (2012) EBMによるがん領域の漢方の使い方　ライフサイエンス.
9. 河野 透 (2012) Topics新しい治療法　クローン病の診療ガイド、編集者：NPO法人日本炎症性腸疾患協会.
10. 河野 透, 荒川 哲男, 鳥羽 研二 (2012) 機能性消化器疾患の変遷とその治療　複合的な症状にどう対処するか　漢方の役割　Geriatric Medicine 50(8):965-975.

2011年

1. 武藤 修一, 大西 俊介, 浅香 正博, 武田 宏司 (2011) 加齢による食欲不振のメカニズムとその対策　六君子湯の効果とその作用機序　消化器内科53:247-251.
2. 武田 宏司, 中川 宏治, 武藤 修一, 大西 俊介, 浅香 正博 (2011) 消化器内科領域における漢方　日本東洋心身医学研究 2:37-41.
3. 武田 宏司, 中川 宏治, 桂田 武彦, 平山 剛, 大西 俊介, 細野 秀崇, 浅香 正博 (2011) 薬効モニタリングの実践　過敏性腸症候群　薬局　62:3191-3197.
4. 武田 宏司, 中川 宏治, 大西 俊介 (2011) 神経内分泌ペプチドを介した悪心・嘔吐の制御機構　医学のあゆみ 238:997-1001.
5. 武藤 修一, 大西 俊介, 浅香 正博, 武田 宏司 (2011) 消化器癌化学療法に伴う食欲不振のメカニズムとその対策　消化器内科 52:559-565.
6. 武田 宏司 (2011) 漢方による消化器疾患治療のポイント　過敏性腸症候群　消化器の臨床14:280-284.
7. 武田 宏司, 中川 宏治, 武藤 修一, 大西 俊介, 浅香 正博、細野 秀崇 (2011) IBS（便秘型）?大建中湯　診断と治療　99:817-822.
8. 鈴木 秀和, 屋嘉比 康治, 武田 宏司, 河野 透 (2011) 漢方薬の消化管疾患への応用 The GI Forefront 6:145-153.
9. 武田 宏司 (2011) 胃食道逆流症　治療　96（臨時増刊）：46-47.

2010年

1. 武田 宏司 (2010) 診療ガイドラインに基づく消化器疾患の治療３-ウイルス肝炎　北海道薬剤師会雑誌 27(1):28-37.
2. 武田 宏司 (2010) 診療ガイドラインに基づく消化器疾患の治療４-大腸癌　北海道薬剤師会雑誌 27(2):8-14.
3. 武田 宏司 (2010) シスプラチン投与に伴う食欲不振に対する六君子湯の改善効果 漢方医学 34:38-39.
4. 武田 宏司 (2010) 専門医に聞く　機能性消化管障害　内臓知覚過敏からみた機能性消化管障害(FGIDs)　内臓知覚過敏への胃酸やセロトニンの関与 日本医事新報 4478: C1-C3.
5. 武田 宏司, 中川 宏治, 武藤 修一, 浅香 正博 (2010) 漢方薬から考える栄養不良へのアプローチと創薬への期待 消化器心身医学 17:6-14.
6. 武田 宏司, 武藤 修一, 浅香 正博 (2010) 機能性ディスペプシアに対する漢方処方 カレントテラピー 28:571-575.
7. 武田 宏司, 武藤 修一 (2010) 消化器疾患に対する心身医学的アプローチ　高齢者における食欲不振の病態 日本医事新報 4500:76-80.
8. 武田 宏司 (2010) 消化管疾患と漢方： G.I.Research 18:283-289.
9. 武田 宏司 (2010) 薬に強くなる　下剤・止痢・整腸薬：看護技術 56:71-75.
10. 武田 宏司, 武藤 修一, 大西 俊介, 浅香 正博 (2010) 機能性ディスペプシアおよび食欲不振に対する漢方治療　日本消化器病学会雑誌 107:1586-1591.
11. 小林 正伸, 中川 宏治 (2010) 転移とHypoxia Inducible Factor　癌と化学療法　37:2047-2051.
12. 武田 宏司 (2010) 感染性腸炎　家庭医学大全科（６訂版）法研　1773-1774.
13. 武田 宏司 (2010) 放射線腸炎　家庭医学大全科（６訂版）法研　1774-1775.
14. 武田 宏司 (2010) 過敏性腸症候群　家庭医学大全科（６訂版）法研　1775-1777.
15. 武田 宏司 (2010) 虫垂炎　家庭医学大全科（６訂版）法研　1777-1779.

2009年

1. 武田 宏司 (2009) 過敏性腸症候群update　IBSの診断基準とガイドライン 日本医師会雑誌 137:IBS-1-IBS-4.
2. 武田 宏司 (2009) QOL改善のためのIBS治療の実際　薬物治療に用いる薬剤の特徴とその使い方　漢方薬 消化器の臨床 12:181-185.
3. 武田 宏司, 中川 宏治 (2009) 低酸素誘導因子(HIF) G.I.Research 17:172-174.
4. 武田 宏司, 中川 宏治 (2009) マクロファージ遊走阻止因子(MIF) G.I.Research 17:175-177.
5. 武田 宏司 (2009) FD診療の現状と問題点　大学病院での経験から　消化器心身医学 16:64-71.
6. 武田 宏司, 武藤 修一, 服部 智久, 定金 千春 (2009) FDに対する漢方薬の効果と脳腸相関　セロトニン・グレリンの役割　心身医学 49:807-813.
7. 武田 宏司, 桂田 武彦, 浅香 正博 (2009) 胃潰瘍：日本臨床別冊消化管症候群(上) 287-290.
8. 武田 宏司, 浅香 正博 (2009) 消化性潰瘍治療薬の選び方 月刊レジデント 2:53-56.
9. 武田 宏司, 桂田 武彦, 平山 剛, 浅香 正博 (2009) 潰瘍性大腸炎 日本臨床別冊消化管症候群(下) 294-299.
10. 池田 陽子, 高崎 裕代, 久保 ちづる, 植田 孝介, 柏崎 晴彦, 白石 秀明, 齋藤 伸治, 清水 力, 七戸 俊明, 武田 宏司 (2009) 体重が増え続けて栄養量の設定が困難であった遷延性脳死状態の小児の栄養管理 臨床栄養別冊栄養力UP NST症例集2 2-7.
11. 武田 宏司 (2009) 診療ガイドラインに基づく消化器疾患の治療１-上部消化管疾患　北海道薬剤師会雑誌 26(10):4-11.
12. 武田 宏司 (2009) 診療ガイドラインに基づく消化器疾患の治療２-下部消化管疾患　北海道薬剤師会雑誌 26(11):4-13.
13. 永井 康一, 武田 宏司, 中川 宏治, 浅香 正博, 北川 善政 (2009) HSC-2細胞の炎症反応におけるマクロファージ遊走阻止因子の役割について　北海道歯学雑誌 30:69-79.
14. 折舘 伸彦, 武田 宏司, 目須田 康, 西澤 典子, 浅香 正博, 福田 諭 (2009) 咽喉頭逆流症状に伴う上腹部症状および酸抑制治療効果の検討　潰瘍 36:22-25.
15. 武田 宏司, 服部 智久, 加瀬 義夫, 浅香 正博 (2009) 抗癌剤による食欲不振に対する六君子湯の効果 潰瘍 36:211-215.
16. 武田 宏司, 加藤 元嗣 (2009) 上腸間膜動脈症候群 内科学書（第７版）中山書店　94-96.

2008年

1. 武田 宏司, 山本 純司, 加藤 元嗣, 清水 勇一, 小野 尚子, 浅香 正博 (2008) 他覚所見をどう捉えるか　特殊な内視鏡検査 治療 90:1941-1944.
2. 武田 宏司, 高後 裕、蘆田 知史, 本谷 聡, 坂牧 純夫 (2008) 新しいIBD診療の飛躍に向かって　北海道地区編　研究班プロジェクト「啓蒙活動」のモデルケースとして　IBD Research 2:100-111.
3. 武田 宏司 (2008) 胃食道逆流症　治療 90(臨増):44-45.
4. 武田 宏司, 藤本 一眞, 渡辺 守, 岡崎 和一 (2008) IBD治療の進歩2008　The GI Forefront 4:35-44.
5. 武田 宏司 (2008) 誌上ディベート　FD治療における漢方薬の意義　積極的に使用するとする立場から　Frontiers in Gastroenterology　3:204-211.
6. 武田 宏司, 折舘 伸彦, 浅香 正博 (2008) 咽喉頭酸逆流症(laryngopharyngeal reflux:LPR)　消化器科 47:18-23.
7. 武田 宏司 (2008) 他科の最新トピックスから学ぶ　六君子湯は5-HT2受容体拮抗作用によりアシルグレリン分泌を増加させ、シスプラチンによる食欲不振を改善する　産婦人科漢方研究のあゆみ 25:19-26.
8. 武田 宏司 (2008) 消化器疾患と漢方製剤　The GI Forefront 4:152-154.
9. 亀山 武志, 中川 宏治, 多田 光宏, 浜田 淳一, 柏崎 晴彦, 伊川 真弓, ヌル・モハメド・モンスル・ハッサン, 守内 哲也, 井上 農夫男 (2008) チロシンホスファターゼPRL-3によるp53の転写活性制御　北海道歯学雑誌 28:81-92.
10. 吉川 和人, 多田 光宏, 浜田 淳一, 中川 宏治, 亀山 武志, 鈴木友 希子, 伊川 真弓, 守内 哲也, 北川 善政 (2008) 優性阻害性p53変異体R248QはH1299細胞の浸潤能を増大させる　北海道歯学雑誌 29:237-248.